Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Nature Structural & Molecular Biology|April 7, 2020
Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complexMary E Matyskiela, Thomas Clayton, Xinde Zheng, et al.
Neoplasia (New York, N.Y.)|August 28, 2017
Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic LeukemiaGabriele Gugliotta, Makoto Sudo, Qi Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamideOwen A O'Connor, Emily A Smith, Lorraine E Toner, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2002
Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitorsZhihong Lai, Tao Yang, Young B Kim, et al.
The American Journal of Pathology|October 28, 2003
Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cellsJanardhan Sampath, Pandy R Long, Robert L Shepard, et al.
European Journal of Immunology|May 1, 2009
Defensin-related peptide 1 (Defr1) is allelic to Defb8 and chemoattracts immature DC and CD4+ T cells independently of CCR6Karen Taylor, Mark Rolfe, Natalie Reynolds, et al.
American Journal of Clinical Pathology|October 19, 2004
Targeted therapies for cancer 2004Jeffrey S Ross, David P Schenkein, Robert Pietrusko, et al.
Blood Advances|April 13, 2021
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screenZhongying Mo, Scott Wood, Shawn Namiranian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activityJosep Domingo-Domenech, Cristina Oliva, Ana Rovira, et al.
Cell Cycle (Georgetown, Tex.)|September 25, 2007
Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicinMaria A Tapia, Irene González-Navarrete, Alba Dalmases, et al.
Pageof 5